TORONTO, April 5,
2024 /CNW/ - Think Research Corporation (TSXV: THNK)
("Think" or the "Company"), is pleased to announce
the positive outcome of the shareholder vote at yesterday's special
meeting (the "Meeting") of the holders
("Shareholders") of common shares in the capital of the
Company ("Shares") to approve the previously announced plan
of arrangement under the Business Corporations Act
(Ontario) (the
"Arrangement"), pursuant to which Beedie Investments
Ltd. ("Beedie Capital"), will acquire all of the issued
and outstanding Shares, other than those Shares owned by Beedie
Capital and other Shareholders comprised of certain directors and
executive officers of the Company as well as other persons (such
Shareholders, collectively, the "Continuing Shareholders"),
for cash consideration of $0.32 per
Share (collectively, the "Transaction").
At the Meeting, (i) 56,948,252 votes, or approximately 99% of
the votes cast at the Meeting by Shareholders voting virtually or
represented by proxy, were cast in favour of the special resolution
approving the Arrangement (the "Arrangement Resolution");
and (ii) excluding Shares owned by Beedie Capital and the
Continuing Shareholders, which were required to be excluded
pursuant to Multilateral Instrument 61-101 – Protection of
Minority Security Holders in Special Transactions ("MI
61-101"), 32,339,756 votes, or approximately 98% of the
votes cast at the Meeting by Shareholders voting virtually or
represented by proxy, were cast in favour of the Arrangement
Resolution. The Arrangement Resolution was required to be
passed by (i) at least two-thirds (66 2/3%) of the votes cast at
the Meeting by the Shareholders voting virtually or represented by
proxy; and (ii) a simple majority of the votes cast by the
Shareholders voting virtually or represented by proxy, excluding
Shares required to be excluded pursuant to MI 61-101. Details of
the voting results will be filed under the Company's profile on
SEDAR+ at www.sedarplus.ca.
The Company will apply for a final order of the Ontario Superior
Court of Justice (Commercial List) on April
9, 2024. Closing of the Transaction remains subject to the
satisfaction or waiver of other customary closing conditions
contained in the arrangement agreement entered into between Think
and Beedie Capital on February 15,
2024. Assuming the satisfaction or waiver of these
conditions, the Arrangement is anticipated to be completed in the
second quarter of 2024.
Shareholder Questions and
Assistance
Registered Shareholders must submit any certificates and/or DRS
advices representing their Shares, together with a duly completed
and executed letter of transmittal and any other documents that TSX
Trust Company, who is acting as depositary under the Arrangement,
may reasonably require, in order to receive the cash consideration
to which they are entitled under the Arrangement.
Shareholders who have questions or require assistance with
submitting their Shares to the Arrangement may direct their
questions to the Company's strategic shareholder advisor and
proxy solicitation agent, Morrow Sodali at 1-888-444-0591 toll free
in North America or 1-289-695-3075
collect outside North America or
by email at assistance@morrowsodali.com. Further information about
submitting your Shares to the Arrangement, including with respect
to completing the letter of transmittal, may be addressed to TSX
Trust Company toll free at 1-866-600-5869 or by email at
tsxtis@tmx.com.
Forward Looking
Information
This press release contains "forward-looking information" within
the meaning of applicable securities laws. Forward-looking
information may be identified by statements including words such
as: "anticipate," "intend," "plan," "budget," "believe," "project,"
"estimate," "expect," "scheduled," "forecast," "strategy,"
"future," "likely," "may," "to be," "could,", "would," "should,"
"will" and similar references to future periods or the negative or
comparable terminology, as well as terms usually used in the future
and the conditional.
Statements including forward-looking information may include,
without limitation, the timing of various steps to be completed in
connection with the completion of the Transaction. Forward-looking
information is based on assumptions that may prove to be incorrect,
including but not limited to, that the parties will receive, in a
timely manner and on satisfactory terms, the necessary court
approval, and that the parties will otherwise be able to satisfy,
in a timely manner, the other conditions to the closing of the
Transaction, and current expectations and analyses made by the
Company and its management in light of experience and perception of
historical trends, current conditions and expected future
developments, as well as other factors appropriate under the
circumstances. The Company considers these assumptions to be
reasonable in the circumstances. However, there can be no assurance
that such assumptions will reflect the actual outcome of such items
or factors. By its nature, forward-looking information involves
known and unknown risks, uncertainties, changes in circumstances
and other factors that are difficult to predict and many of which
are outside of the Company's control which may cause actual results
to differ materially from the any future or potential results
expressed or implied by such forward-looking information. Important
factors that could cause actual results to differ materially from
those indicated in the forward-looking information include, among
others, (i) the possibility that the Transaction will not be
completed on the terms and conditions, or on the timing, currently
contemplated, and that it may not be completed at all, due to a
failure to obtain or satisfy, in a timely manner or otherwise,
required court approval and other conditions of closing necessary
to complete the Transaction or for other reasons; (ii) the
possibility of adverse reactions or changes in business resulting
from the completion of the Transaction; (iii) risks relating to the
Company's ability to retain and attract key personnel during the
interim period; (iv) the possibility of litigation relating to the
Transaction; (v) risks related to diverting management's attention
from the Company's ongoing business operations; and (vi) other
risks inherent to the business carried out by the Company and
factors beyond its control which could have a material adverse
effect on the Company or its ability to complete the Transaction.
The Company has assumed that the risk factors referred to above
will not cause such forward-looking statements and information to
differ materially from actual results or events. The reader is
cautioned to consider these and other factors, uncertainties and
potential events carefully and not to put undue reliance on
forward-looking statements.
Other than as specifically required by applicable Canadian
securities law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made, whether as a result of
new information, future events or results, or otherwise.
About Think Research
Corporation
Think Research Corporation is an industry leader in delivering
knowledge-based digital health software solutions. The Company's
focused mission is to organize the world's health knowledge so
everyone gets the best care. Its evidence-based healthcare
technology solutions support the clinical decision-making process
and standardization of care to facilitate better health care
outcomes. The Company gathers, develops, and delivers
knowledge-based solutions globally to customers including
enterprise clients, hospitals, health regions, healthcare
professionals, and / or governments. The Company has gathered a
significant amount of data by building its repository of knowledge
through its network and group of companies.
The Company licenses its solutions to over 14,200 facilities for
over 320,000 primary care, acute care, and long-term care doctors,
nurses and pharmacists that rely on the content and data provided
by the Company to support their practices. Millions of patients and
residents annually receive better care due to the essential data
that the Company produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and
clinical trial data via its BioPharma Services subsidiary.
BioPharma Services is a leading provider of bioequivalence and
Phase 1 clinical research services to pharmaceutical companies
globally. The Company's other services include a network of
digital-first primary care clinics and medical clinics that provide
elective surgery. Visit www.thinkresearch.com for more details.
About Beedie Capital
Beedie Capital is a multi-strategy direct investment platform
that manages the alternative investments for Beedie, one of the
largest private companies in Western
Canada. It deploys capital using a flexible, evergreen
mandate, and applies a highly agnostic approach to the duration,
structure and size of its investments. Beedie Capital combines the
strategic capabilities of an institutional investment platform with
the flexibility and entrepreneurial mindset of a privately owned
business. Beedie Capital invests in any sector, with a core focus
on Technology, Tech-enabled Services, and Metals and Mining, and
seeks to grow its invested capital alongside the enterprise value
of its investments. For further information on Beedie Capital,
please visit www.beediecapital.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Think Research Corporation